FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Buy Rating On Shares Of Edwards Lifesciences

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We keep our 12-month price target at $96, 32x our 2026 EPS forecast, a small premium to EW's three-year historical forward average of 30.2x. Our target represents a multiple to health care equipment peers, supported by attractive EPS growth potential from EW's position in the structural heart disease market, as well as EW's negative net debt position, in our view. We raise our 2026 EPS estimate by $0.04 to $3.00 and raise our 2027 estimate by $0.05 to $3.36. We expect near 11.0% sales growth in 2026, building off of 11.6% growth in 2025, supported by procedure volume growth in the U.S. and abroad. EW anticipates a Q4 U.S. launch of PASCAL (transcatheter valve repair) for tricuspid patients (part of the TMTT segment). The company also sees the TRIFORMIS surgical tricuspid valve launching in 2H 2026 (part of the Surgical segment).

Related Articles

Research

Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.

$WAB
Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Centerpoint Energy, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target by $1 to $47, 24.1x our next-12-month EPS estimate, a premium to CNP's five-year average of 19.7x. Our 2026 EPS view is unchanged at $1.91, and we initiate our 2027 EPS view at $2.08. EPS guidance was maintained during Q1 earnings, and the $65.5B 10-year capital investment plan was reaffirmed. Notably, this was the first quarter in nearly two years without an increase to the 10-year capital plan. However, management is evaluating over $10B in incremental opportunities and expects to provide updates following a transmission planning refresh in 2H 2026. The company sees 11% or higher rate base growth potential through 2030, which we think would be among the fastest in the multi-utilities sub-industry. In the longer term, we look favorably on CNP's 7%-9% adjusted EPS CAGR target through 2035, with expectations of reaching the 8%-9% mark from 2026-2028, both of which would likely lead most peer utilities, in our view.

$CNP
Research

Research Alert: Ndaq: Q1 Earnings Beat As Financial Technology Surges

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Nasdaq Inc. (NDAQ) posted solid Q1 2026 results with operating EPS of $0.96 vs. $0.79 a year ago, beating consensus by $0.03, while net revenue of $1.41B rose 14% Y/Y and beat estimates by 2%. Operating margin expanded 170 bps to 56.8%, demonstrating strong operational leverage alongside accelerating revenue growth for two consecutive quarters. Financial Technology exploded 20% higher with record Q1 ACV bookings up 50%+ Y/Y, as Verafin added 58 new clients and Agentic AI gained traction with 500+ clients in production. Market Services delivered record results with 13% growth supported by record industry volumes, while Index options revenue more than doubled for the third consecutive quarter. The Index business showed resilience with $6B in Q1 net inflows and record average ETP AUM of $877B. We view these results as strong validation of NDAQ's diversified growth strategy, with innovation-driven products from the past five years accounting for 46% of trailing-12-month net inflows.

$NDAQ